The Charlie Landers Foundation is dedicated to supporting Pediatric Ewing Sarcoma research through significant funding opportunities. Please check back in October for information on our 2025 Grant Cycle.
Grants range from $20,000-$150,000 with the potential for a second year of funding based on demonstrated progress and joint approval.
Both new and established researchers with their MD, PhD, or dual MD PhD are invited to apply for a CL7 research grant.
In a landmark moment for The Charlie Landers Foundation, we're proud to announce the allocation of over $300,000 towards our second round of research grants aimed at defeating Ewing Sarcoma.
This funding will empower leading researchers and their innovative studies, marking a significant stride in our quest for a cure.
"In order to get people to come up with a cure for Ewing’s Sarcoma, you need people studying Ewing’s sarcoma, focus on the young investigators."
Dr. Michael Kinnaman
Memorial Sloan Kettering Cancer Center
Innovative and transformative pre-clinical, translational, and clinical research, that has the potential to immediately impact the lives of Ewing's sarcoma patients. CL7 Grants awarded in 2023 totaling $350,014. Below are the studies that we funded in our previous grant cycle.
“The role of galectin- 3 in metastatic Ewing Sarcoma” conducted by Dr. Kelly M. Bailey.
"Targeting DNA replication stress in Ewing sarcoma tumors" conducted by Dr. David Gordon.
“Clinical Translation of circulating tumor DNA (ctDNA) liquid biopsies for patients with Ewing sarcoma” conducted by Dr. David Shulman.
"Dissecting and targeting PAK4-mediated signaling in Ewing sarcoma development and metastasis” conducted by Dr. Jason T. Yustein
The Charlie Landers Foundation supports innovative and transformative pre-clinical, translational, and clinical research that has the potential to immediately impact the lives of Ewing’s sarcoma patients.
Your research could help save lives. Inquire about our grants today and see how you can make a difference.
